More research suggests health impacts may be short-lived for many patients once they stop taking GLP-1 receptor agonists.
Researchers have tracked 308 patients who underwent nine months of treatment with tirzepatide before stopping, finding that 96% gained weight in the year after withdrawing, including 9% who ended with more weight than they had before treatment.
Patients who regained the most weight also saw the largest rebound in terms of blood pressure and glucose levels.
The findings, published in JAMA Internal Medicine last month, are the first to show a clear association between weight regain and negative cardiometabolic changes following tirzepatide withdrawal, according to the US researchers.
×
Sign in
If this is your first visit to the new AusDoc website, reset your password
here.